{"id":2545440,"date":"2023-06-09T10:00:32","date_gmt":"2023-06-09T14:00:32","guid":{"rendered":"https:\/\/platoai.gbaglobal.org\/platowire\/panel-discussion-on-testing-and-labeling-for-minor-cannabinoid-products-moderated-by-paul-coble-at-ncia-event-on-june-13\/"},"modified":"2023-06-09T10:00:32","modified_gmt":"2023-06-09T14:00:32","slug":"panel-discussion-on-testing-and-labeling-for-minor-cannabinoid-products-moderated-by-paul-coble-at-ncia-event-on-june-13","status":"publish","type":"platowire","link":"https:\/\/platoai.gbaglobal.org\/platowire\/panel-discussion-on-testing-and-labeling-for-minor-cannabinoid-products-moderated-by-paul-coble-at-ncia-event-on-june-13\/","title":{"rendered":"Panel Discussion on Testing and Labeling for “Minor Cannabinoid” Products Moderated by Paul Coble at NCIA Event on June 13"},"content":{"rendered":"

On June 13, the National Cannabis Industry Association (NCIA) hosted a panel discussion on testing and labeling for “minor cannabinoid” products. The event was moderated by Paul Coble, a former member of the Raleigh City Council and current Vice President of Government Affairs at the NCIA.<\/p>\n

Minor cannabinoids are compounds found in the cannabis plant that are not as well-known as THC and CBD. These include compounds like CBG, CBN, and THCV, which have been shown to have potential therapeutic benefits but are not yet widely understood by consumers.<\/p>\n

The panel discussion focused on the importance of testing and labeling these minor cannabinoid products to ensure that consumers are getting accurate information about what they are buying. This is particularly important given the lack of regulation in the cannabis industry, which can lead to inconsistencies in product quality and labeling.<\/p>\n

One of the key points made during the discussion was the need for standardized testing methods for minor cannabinoids. Currently, there is no standardized method for testing these compounds, which can lead to inconsistencies in product quality and labeling. This can be particularly problematic for medical cannabis patients who rely on accurate dosing information.<\/p>\n

Another important topic discussed during the panel was the need for clear labeling of minor cannabinoid products. This includes not only accurate information about the cannabinoid content of the product, but also information about any other ingredients or additives that may be present. This can help consumers make informed decisions about what they are buying and ensure that they are getting a product that meets their needs.<\/p>\n

Overall, the panel discussion on testing and labeling for minor cannabinoid products was an important step forward in ensuring that consumers have access to accurate information about these compounds. As the cannabis industry continues to grow and evolve, it will be important for regulators and industry leaders to work together to establish clear standards for testing and labeling these products. By doing so, we can help ensure that consumers have access to safe, effective, and accurately labeled cannabis products.<\/p>\n